Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock

Disc Medicine (NASDAQ: IRON), a clinical-stage biopharmaceutical company, announced the pricing of an upsized underwritten public offering of 6 million shares at $75 per share, generating $450 million in gross proceeds. The company plans to use the funds for research and clinical development of product candidates, including bitopertin for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and general corporate purposes. The offering is expected to close on October 22, 2026.